首页> 美国卫生研究院文献>Journal of Genetic Engineering Biotechnology >Assessment of Ki-67 as a potential biomarker in patients with breast cancer
【2h】

Assessment of Ki-67 as a potential biomarker in patients with breast cancer

机译:Ki-67作为乳腺癌患者潜在生物标志物的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Breast cancer is the most common cancer in females, it accounts for one third of all malignancies affecting women. Appropriate biomarkers play significant role in predicting the prognosis and decide the specific therapy to each patient. In this study we aimed at evaluating the value of Ki-67 as a prognostic marker in breast cancer patients and to analyze the associations between Ki-67 and their clinicopathological parameters. This study included 92 patients with developed non metastatic breast cancer and 10 women had benign breast tumor served as controls. We measured the serum level by ELISA technique and tissue expression of Ki-67 by immunohistochemical technique. Our results showed that there were no statistically significant differences in serum Ki-67 levels between the two studied groups. As for Ki-67expression in breast cancer cells, the score increases with increase of tumor size, grade, premenopausal, Ki-67 expression in estrogen and progesterone receptor positive tumors showed lower values than estrogen and progesterone negative tumors, while higher Ki-67 expression was more frequently associated with HER2-positive. In conclusion; our study supports the finding that tissue Ki-67 expression may add prognostic information to that obtained from classical prognostic factors and can provide data of significant value to other important prognostic indicators such as pathological grading, and axillary lymph node involvement.
机译:乳腺癌是女性中最常见的癌症,占影响妇女的所有恶性肿瘤的三分之一。适当的生物标志物在预测预后和决定针对每个患者的具体治疗中起重要作用。在这项研究中,我们旨在评估Ki-67作为乳腺癌患者预后指标的价值,并分析Ki-67与他们的临床病理参数之间的关联。这项研究包括92例发展为非转移性乳腺癌的患者和10例患有良性乳腺肿瘤的妇女作为对照。我们通过ELISA技术测量血清水平,并通过免疫组织化学技术测量Ki-67的组织表达。我们的结果表明,两个研究组之间的血清Ki-67水平无统计学差异。至于乳腺癌细胞中Ki-67的表达,分数随肿瘤大小,等级,绝经前,雌激素和孕激素受体阳性肿瘤中Ki-67表达的增加而降低,而其值却高于雌激素和孕激素阴性肿瘤,而Ki-67表达较高。与HER2阳性相关性更高。结论;我们的研究支持以下发现:组织Ki-67表达可能会增加从经典预后因素获得的预后信息,并且可以为其他重要的预后指标(例如病理分级和腋窝淋巴结受累)提供重要价值的数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号